enGene: Funding, Investors & Team (Sep 2026)
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
enGene has raised $83.8M across 3 funding rounds on record, the most recent an undisclosed round of $18.0M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
enGene Company Profile and Key Stats
Latest funding round on record: Jan 2026.
enGene Funding Rounds
enGene raised $22.5M in an undisclosed round announced in Dec 2023.
10 months later, an undisclosed round of $43.3M was announced in Oct 2024.
1.3 years later, an undisclosed round of $18.0M was announced in Jan 2026.
enGene Founders and Leadership Team
No contact details are on record for this team yet.
enGene Funding Compared to Other Biotechnology Startups
enGene's latest round of $18.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like enGene in Biotechnology and Vancouver
Companies Similar to enGene
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
enGene Funding FAQs
What does enGene do?
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
How much funding has enGene raised?
enGene has raised $83.8M across 3 rounds on record. The most recent is an undisclosed round of $18.0M announced in Jan 2026.
When did enGene last raise funding?
enGene's most recent funding round on record is an undisclosed round of $18.0M, announced in Jan 2026.
Who founded enGene?
FundedIQ lists Timothy J Kieffer (Founder) at enGene.
Where is enGene headquartered?
enGene is based in Vancouver, British Columbia, Canada.
How many employees does enGene have?
enGene is in the 51-100 employee band.
How does enGene's funding compare to other Biotechnology startups?
enGene's latest round of $18.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's enGene Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for enGene is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.